NASHUA, NH, May 18, 2022 (GLOBE NEWSWIRE) — iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and treatment solutions, today announced that new research supporting ProFound AI® for digital breast tomosynthesis (DBT) will be presented at the Society of Breast Imaging (SBI/ACR) Breast Imaging Symposium, May 16-19 in Savannah, Georgia. The company is also showcasing its comprehensive suite of deep learning solutions for breast cancer detection, density assessment and risk assessment at the iCAD booth (#504) during the meeting.
In an oral presentation today at 1:30 p.m. EDT, Colleen Madden, MD, FACR, assistant clinical professor of radiology at IUH Ball Memorial Hospital at Indiana University School of Medicine, will present the promising results. of a retrospective study titled “Real-World Breast Cancer Detection Before and After Implementing an Artificial Intelligence Detection System in a Digital Breast Tomosynthesis Screening Program. According to the results of the study, the he use of ProFound AI in clinical practice with DBT, or 3D mammography, has significantly improved screening performance for radiologists, improved cancer detection rates, and reduced false positive rates.
“This recent investigator-initiated study confirms that ProFound AI offers invaluable insights that help radiologists identify cancers more efficiently and accurately, which could significantly improve patient outcomes,” said Stacey Stevens, President and CEO of iCAD, Inc. “iCAD is the only company to provide a complete portfolio of unparalleled products1 AI solutions designed to help radiologists detect cancers earlier, while reducing false positives and unnecessary patient callbacks,1.2 which can cause unnecessary stress to a woman and her family.
The first AI cancer detection software for DBT to be cleared by the FDA, ProFound AI is clinically proven to deliver superior performance, reduce radiologist read time by 52.7%, improve radiologist sensitivity by 8%, and Reduce unnecessary patient call rates by 7.2%.2 The latest generation of ProFound AI delivers up to 10% improvement in specificity performance, compared to previous versions of the technology, while maintaining industry-leading high sensitivity and approximately 40% processing faster on the new PowerLook platform.3
“Overall, this real-world study suggests that ProFound AI can help radiologists detect more cancers, and with greater accuracy, indicating that this innovative tool can not only improve clinical performance, but also potentially improve patient outcomes. patient outcomes,” said Dr. Madden. “While AI does not eliminate the need for radiologists, it greatly expands their capabilities, as it greatly assists clinicians in examining large DBT datasets and ultimately delivering quality care to our patients. We are delighted that this study contributes to the growing body of research that demonstrates the value of AI in breast cancer screening.
“We are committed to helping radiologists transform breast cancer screening and detection by reducing the time to read and improving the accuracy of their reading, with up to two times the improvement in clinical performance compared to leading competitors”,1 Stevens added. “These latest data indicate that ProFound AI significantly improves the performance of radiologists and helps reduce their workload, allowing them to spend more time with patients and deal with potentially complex additional cases.”
iCAD’s Breast AI Suite also includes PowerLook® Breast Density Assessment, which helps with accurate and consistent density-based stratification and reporting, and ProFound AI® Risk, the first and only decision support tool clinic in the world that provides accurate short-term breast cancer assessment. a truly personalized risk estimate for each woman, based on age, breast density and mammographic characteristics.
About iCAD, Inc.
Based in Nashua, NH, iCAD® is a global medical technology leader providing innovative cancer detection and treatment solutions. For more information, visit www.icadmed.com and www.xofinc.com.
Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expected benefits of ProFound AI®, the benefits of the Company’s products, factors affecting the market for our products, the behavior of customers and potential customers, and the future prospects for the Company’s technology platforms and products. These forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied. -understood by these statements. forward-looking statements. These factors include, but are not limited to, the Company’s ability to achieve its business and strategic objectives, the willingness of patients to undergo mammography screening in light of the risks of potential exposure to Covid-19, if the Mammography screening will be treated as an essential procedure, if ProFound AI will improve read efficiency, improve specificity and sensitivity, reduce false positives, and otherwise prove more beneficial to patients and clinicians, the impact of supply and manufacturing constraints or difficulties over our ability to fulfill our orders, uncertainty of future sales levels, to defend against litigation, protection of patents and other proprietary rights, market acceptance of products, obsolescence possible product technology, increased competition, government regulation, changes in Medicare or other reimbursement policies, ri risks related to our existing and future debt, competitive factors, the effects of a decline in the economy or the markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words ‘believe’, ‘demonstrate’, ‘intend’, ‘expect’, ‘estimate’, ‘will’, ‘continue’, ‘anticipate’, ‘likely’, ‘seek’ and Similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide updates to the information contained in this release. For additional information regarding these and other risks that iCAD faces, please see the information contained in our public filings with the Securities and Exchange Commission, available in the Investors section of our website at http:/ /www.icadmed.com and on the SEC website. website at http://www.sec.gov.
Jessica Burns, iCAD
iCAD Investor Relations
- https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm. Accessed 01/19/22. FDA 510K submissions K182373, K201019, K193229.
- Conant, E et al. (2019). Improving accuracy and efficiency through the simultaneous use of artificial intelligence for digital breast tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed through https://pubs.rsna.org/doi/10.1148/ryai.2019180096.
- iCAD data on file. Standalone performance varies by vendor. FDA cleared.